What is Saxenda® (Liraglutide)?
Saxenda (liraglutide) is an FDA-approved prescription injection designed for chronic weight management. Produced by Novo Nordisk, Saxenda belongs to the GLP-1 receptor agonist class of medications.
Unlike weekly injections like Wegovy or Zepbound, Saxenda is administered **once daily**, allowing for precise, day-by-day titration and rapid adjustment if side effects occur. Used in conjunction with a reduced-calorie diet and regular exercise, Saxenda helps patients achieve sustained, clinically meaningful weight loss.
How Liraglutide Works: Appetite & Satiety Control
Saxenda is 97% identical to human Glucagon-Like Peptide-1 (GLP-1), a natural digestive hormone released after eating:
- Activates Satiety Signals: Binds to GLP-1 receptors in the hypothalamus, sending fullness signals to the brain and quieting daily food cravings.
- Slows Gastric Emptying: Moderates how quickly food leaves the stomach, prolonging the sensation of satisfaction after smaller meals.
- Metabolic Balance: Helps optimize insulin and glucagon secretion in response to elevated blood glucose levels.
Clinical Trial Evidence: The SCALE Program
In the landmark SCALE (Satiety and Clinical Adiposity—Liraglutide Evidence) Phase 3 clinical trials:
- Significant Weight Reduction: Adults taking the 3.0 mg maintenance dose achieved an average weight loss of 8% of total body weight (approx. 18.5 lbs / 8.4 kg) over 56 weeks compared to placebo.
- Prediabetes Reversal: 69% of individuals with prediabetes at baseline achieved normal blood sugar status after 56 weeks on Saxenda.
- Cardiometabolic Risk Reductions: Patients experienced significant improvements in waist circumference, fasting lipid levels, and systolic blood pressure.
5-Week Daily Dosing & Titration Schedule
Each Saxenda pen contains 18 mg of liraglutide and delivers pre-set doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg. To minimize gastrointestinal symptoms, patients follow a gradual 5-week dose escalation:
| Stage | Schedule | Schedule | Purpose |
|---|---|---|---|
| Week 1 | Days 1–7 | 0.6 mg daily | Initiation & digestive adaptation |
| Week 2 | Days 8–14 | 1.2 mg daily | Early dose escalation |
| Week 3 | Days 15–21 | 1.8 mg daily | Mid-stage adjustment |
| Week 4 | Days 22–28 | 2.4 mg daily | Pre-therapeutic step |
| Week 5+ | Day 29 onward | 3.0 mg daily | Full therapeutic maintenance dose |
Inject subcutaneously into the abdomen, thigh, or upper arm once every day at any time of day, with or without meals.
Frequently Asked Questions (FAQ)
What is the difference between Saxenda and Victoza?
Both medications contain the active ingredient **liraglutide** from Novo Nordisk. However:
Saxenda is FDA-approved for chronic weight management with a target maintenance dose of 3.0 mg daily.
Victoza is FDA-approved for type 2 diabetes management at lower maintenance doses of 1.2 mg or 1.8 mg daily.
What is the difference between Saxenda and Wegovy?
Frequency: Saxenda is a once-daily injection (liraglutide), whereas Wegovy is a once-weekly injection (semaglutide).
Average Weight Loss: Semaglutide (Wegovy) averages ~15% weight reduction, compared to ~8% for liraglutide (Saxenda). However, Saxenda’s shorter half-life means it leaves the system faster if a patient experiences sensitivity or side effects.
What are the most common side effects?
The most frequent side effects are gastrointestinal (nausea, diarrhea, constipation, vomiting, headache, and low blood sugar in patients with T2D). These symptoms are typically mild to moderate and subside after the first few weeks on each dose level.
How should Saxenda pens be stored?
Unused pens: Keep in the refrigerator between 36°F and 46°F (2°C to 8°C). Do not freeze.
In-use pen: Store at room temperature between **59°F and 86°F (15°C to 30°C)** or in the refrigerator for up to 30 days. Keep the pen cap on when not in use to protect from sunlight.



Reviews
There are no reviews yet.